Aprea Therapeutics, Inc. 8-K

What Happened
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on January 9, 2026 (Item 8.01) to report an updated corporate presentation slide deck. The presentation is filed as Exhibit 99.1 and is incorporated by reference into the filing. The 8-K was signed by Oren Gilad, Ph.D., President and Chief Executive Officer.

Key Details

• Filing date: January 9, 2026 (Form 8-K, Item 8.01 — Other Events).
• Exhibit filed: Exhibit 99.1 — "Corporate Presentation (January 2026)".
• Signature: Signed by Oren Gilad, Ph.D., President & CEO, on behalf of the registrant.
• The 8-K does not include earnings, financial statements, or other operational disclosures beyond the slide deck filing.

Why It Matters
Filing an updated corporate presentation is a primary way the company communicates strategy, pipeline status, milestones and investor messaging. While this 8-K did not report financial results or other material events, investors should review Exhibit 99.1 for any substantive updates or clarifications about Aprea’s business, product pipeline, or corporate plans that could affect investment decisions.